Richard D Carvajal Selected Research

T-Cell Antigen Receptors (T-Cell Receptor)

12/2023	Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
11/2022	Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
10/2022	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
1/2022	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
7/2019	Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard D Carvajal Research Topics

Disease

77	Neoplasms (Cancer) 01/2024 - 12/2006
73	Melanoma (Melanoma, Malignant) 01/2024 - 04/2010
41	Uveal melanoma 12/2023 - 04/2011
14	Neoplasm Metastasis (Metastasis) 01/2023 - 10/2013
9	Disease Progression 02/2023 - 04/2014
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 06/2012
7	Fatigue 11/2022 - 01/2009
7	Sarcoma (Soft Tissue Sarcoma) 11/2022 - 05/2012
6	Fever (Fevers) 12/2023 - 01/2019
5	Nausea 01/2021 - 12/2009
4	Diarrhea 01/2021 - 01/2009
4	Neutropenia 04/2015 - 01/2009
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2024 - 06/2015
3	Exanthema (Rash) 12/2023 - 01/2018
3	COVID-19 01/2022 - 01/2021
3	Skin Neoplasms (Skin Cancer) 01/2021 - 01/2018
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/2019 - 03/2012
2	Pruritus (Itching) 12/2023 - 01/2021
2	Injection Site Reaction 11/2022 - 08/2010
2	Squamous Cell Carcinoma of Head and Neck 01/2021 - 01/2020
2	Vomiting 01/2021 - 12/2009
2	Carcinogenesis 06/2019 - 07/2012
2	Hypertension (High Blood Pressure) 08/2017 - 11/2015
2	Hypersensitivity (Allergy) 01/2017 - 08/2010
2	Brain Neoplasms (Brain Tumor) 07/2015 - 05/2015
2	Colorectal Neoplasms (Colorectal Cancer) 06/2012 - 11/2010
2	Hyponatremia 04/2011 - 12/2009
1	Mesothelioma 01/2024
1	Triple Negative Breast Neoplasms 01/2024
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 12/2023

Drug/Important Bio-Agent (IBA)

17	IpilimumabIBA 12/2023 - 04/2010
13	Proteins (Proteins, Gene)FDA Link 12/2023 - 04/2011
11	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 09/2011
11	Immune Checkpoint InhibitorsIBA 01/2022 - 04/2014
10	Monoclonal AntibodiesIBA 01/2021 - 04/2014
9	tebentafuspIBA 12/2023 - 07/2019
8	AZD 6244IBA 01/2018 - 07/2012
7	pembrolizumabIBA 12/2023 - 01/2016
7	Dacarbazine (DIC)FDA LinkGeneric 12/2023 - 06/2014
7	NivolumabIBA 02/2023 - 04/2014
6	Imatinib Mesylate (Gleevec)FDA Link 11/2022 - 05/2011
6	alvocidib (flavopiridol)IBA 11/2012 - 01/2009
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023 - 07/2019
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2013
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 08/2010
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2023 - 06/2015
4	Phosphotransferases (Kinase)IBA 01/2023 - 12/2006
4	AntibodiesIBA 11/2022 - 06/2013
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022 - 06/2011
4	Mitogen-Activated Protein KinasesIBA 01/2022 - 10/2013
4	Protein Kinase CIBA 01/2022 - 10/2013
3	HLA-A Antigens (HLA-A)IBA 12/2023 - 01/2021
3	CytokinesIBA 10/2022 - 01/2021
3	sotrastaurinIBA 01/2022 - 01/2020
3	AntigensIBA 02/2021 - 06/2013
3	LigandsIBA 11/2019 - 06/2012
3	Docetaxel (Taxotere)FDA Link 11/2015 - 01/2009
3	B7-H1 AntigenIBA 03/2015 - 06/2013
2	spartalizumabIBA 01/2024 - 01/2022
2	Glycoproteins (Glycoprotein)IBA 12/2023 - 01/2021
2	VaccinesIBA 11/2022 - 01/2017
2	HLA-A*02:01 antigenIBA 10/2022 - 08/2010
2	tremelimumabIBA 01/2022 - 10/2021
2	durvalumabIBA 01/2022 - 10/2021
2	LY3022855IBA 10/2021 - 01/2021
2	Arginine (L-Arginine)FDA Link 01/2021 - 04/2013
2	EnzymesIBA 01/2021 - 04/2013
2	Immunoglobulin G (IgG)IBA 01/2021 - 01/2018
2	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2020
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021 - 12/2014
2	talimogene laherparepvecIBA 06/2020 - 10/2017
2	Melphalan (Alkeran)FDA LinkGeneric 01/2020 - 04/2019
2	VemurafenibIBA 10/2019 - 07/2015
2	Peptides (Polypeptides)IBA 07/2019 - 04/2011
2	HLA Antigens (Human Leukocyte Antigens)IBA 07/2019 - 08/2010
2	Dasatinib (BMS 354825)FDA Link 06/2019 - 06/2017
2	nilotinib FDA Link 06/2019 - 05/2015
2	Tyrosine Kinase InhibitorsIBA 06/2019 - 05/2015
2	PLX51107IBA 01/2019 - 01/2019
2	ontuxizumabIBA 01/2018 - 03/2015
2	Gemcitabine FDA Link 11/2015 - 01/2015
2	Immunoglobulins (Immunoglobulin)IBA 06/2015 - 06/2015
2	Temozolomide (Temodar)FDA LinkGeneric 06/2015 - 06/2014
2	Carboplatin (JM8)FDA LinkGeneric 04/2015 - 06/2012
2	PlatinumIBA 04/2015 - 12/2009
2	Alkaline PhosphataseIBA 04/2015 - 12/2011
2	CTLA-4 AntigenIBA 01/2015 - 01/2014
2	GTP-Binding Proteins (G-Protein)IBA 08/2014 - 07/2012
2	Irinotecan (Camptosar)FDA LinkGeneric 11/2012 - 11/2010
2	MitogensIBA 07/2012 - 09/2011
2	Cisplatin (Platino)FDA LinkGeneric 06/2012 - 04/2011

Therapy/Procedure

64	Therapeutics 01/2024 - 12/2006
20	Immunotherapy 08/2023 - 06/2013
12	Drug Therapy (Chemotherapy) 12/2022 - 06/2013
7	Radiotherapy 01/2023 - 06/2010
3	Aftercare (After-Treatment) 02/2023 - 04/2014
2	Secondary Prevention 01/2020 - 01/2018
2	Neoadjuvant Therapy 04/2019 - 11/2015
2	Drug Tapering 01/2019 - 01/2009
2	Investigational Therapies (Experimental Therapy) 01/2018 - 11/2013